Aletaha, Daniel <br/><br/>
Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.  [electronic resource] 

 -  Arthritis and rheumatism  Dec 2011 
 - 3702-11 p.  digital 
<br/><br/> Publication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1529-0131 
<br/><br/><label>Standard No.: </label>10.1002/art.30634  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antirheumatic Agents--therapeutic use<br/>Arthritis, Rheumatoid--drug therapy<br/>Arthrography<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Drug Therapy, Combination<br/>Female<br/>Humans<br/>Infliximab<br/>Joints--pathology<br/>Male<br/>Methotrexate--therapeutic use<br/>Middle Aged<br/>Outcome Assessment, Health Care--methods<br/>Remission Induction<br/>Retrospective Studies<br/>Severity of Illness Index<br/>Treatment Outcome<br/>Young Adult